🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Robert W. Baird Stick to Their Buy Rating for Blueprint Medicines

Published 02/19/2021, 04:11 AM
BPMC
-


Robert W. Baird analyst Michael Ulz reiterated a Buy rating on Blueprint Medicines (NASDAQ:BPMC) on Thursday, setting a price target of $120, which is approximately 24.04% above the present share price of $96.74.

Ulz expects Blueprint Medicines to post earnings per share (EPS) of $11.49 for the first quarter of 2021.

The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Blueprint Medicines, with an average price target of $118.09.
The analysts price targets range from a high of $152 to a low of $81.

In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $745.12 million and a net profit of $633.37 million. The company's market cap is $5.39 billion.

According to TipRanks.com, Robert W. Baird analyst Michael Ulz is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.6% and a 52.63% success rate.

Blueprint Medicines Corp . is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.